New agents for Alzheimer's disease and other neurological disorders reported in recent patents July 3, 2008
Genmab receives milestone payment from GSK for initiation of phase II study of ofatumumab July 3, 2008
Myriad Genetics to discontinue development of Flurizan following disappointing phase III results July 2, 2008
RSS